Literature DB >> 31760172

The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis.

Moisés Selman1, Annie Pardo2.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive and devastating interstitial lung disease of unknown etiology, where the normal lung architecture is lost and replaced by fibrotic tissue leading to an irreversible and progressive respiratory insufficiency. Historically, IPF was considered a chronic inflammatory disorder, which gradually progressed to established fibrosis. However, strong clinical and experimental evidence indicates that the disease represents an epithelial-driven disorder which results from a complex interplay of genetic and environmental risk factors, aging-associated processes and a profibrotic epigenetic reprogramming. The convergence of these factors results in the aberrant activation of epithelial cells that initiate the development of the disease, producing virtually all the mediators that participate in the migration, proliferation and activation of fibroblasts, their differentiation to myofibroblasts and the excessive and chaotic secretion of extracellular matrix proteins. Although progress has been made in understanding the causes and consequences of this abnormal behavior of distal airways and alveolar epithelium, the mechanisms that initiate and perpetuate the vicious circle of multidirectional abnormal communications between the epithelium and fibroblasts and other resident cells have not been elucidated. In this review, we discuss the role of epithelial cells and the mechanisms underlying the fibrotic response in IPF, and highlight some promising therapeutic targets for these cells.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aging; Epithelial cells; IPF; Pulmonary fibrosis; Single-cell RNAseq

Year:  2019        PMID: 31760172     DOI: 10.1016/j.cellsig.2019.109482

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  45 in total

Review 1.  Update in Interstitial Lung Disease 2019.

Authors:  Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson
Journal:  Am J Respir Crit Care Med       Date:  2020-08-15       Impact factor: 21.405

2.  WNT Signalling in Lung Physiology and Pathology.

Authors:  Yan Hu; Chiara Ciminieri; Qianjiang Hu; Mareike Lehmann; Melanie Königshoff; Reinoud Gosens
Journal:  Handb Exp Pharmacol       Date:  2021

Review 3.  Regeneration-Associated Transitional State Cells in Pulmonary Fibrosis.

Authors:  Mengxia Shen; Ziqiang Luo; Yan Zhou
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

Review 4.  Lung Fibrosis and Fibrosis in the Lungs: Is It All about Myofibroblasts?

Authors:  Elena Ortiz-Zapater; Jaime Signes-Costa; Paula Montero; Inés Roger
Journal:  Biomedicines       Date:  2022-06-15

5.  Evaluation of Correlations between Genetic Variants and High-Resolution Computed Tomography Patterns in Idiopathic Pulmonary Fibrosis.

Authors:  Elisa Baratella; Barbara Ruaro; Fabiola Giudici; Barbara Wade; Mario Santagiuliana; Francesco Salton; Paola Confalonieri; Michele Simbolo; Aldo Scarpa; Saverio Tollot; Cristina Marrocchio; Maria Assunta Cova; Marco Confalonieri
Journal:  Diagnostics (Basel)       Date:  2021-04-23

6.  AP-3-dependent targeting of flippase ATP8A1 to lamellar bodies suppresses activation of YAP in alveolar epithelial type 2 cells.

Authors:  Seunghyi Kook; Ping Wang; Shufang Meng; Christopher S Jetter; Jennifer M S Sucre; John T Benjamin; Jason J Gokey; Hayley A Hanby; Alexa Jaume; Laura Goetzl; Michael S Marks; Susan H Guttentag
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-18       Impact factor: 12.779

7.  LncRNA CTD-2528L19.6 prevents the progression of IPF by alleviating fibroblast activation.

Authors:  Tingting Chen; Yingying Guo; Jiayi Wang; Liqiang Ai; Lu Ma; Wenxin He; Zhixin Li; Xiaojiang Yu; Jinrui Li; Xingxing Fan; Yunyan Gu; Haihai Liang
Journal:  Cell Death Dis       Date:  2021-06-10       Impact factor: 8.469

Review 8.  COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development.

Authors:  Joowon Yim; Hee Hyun Lim; Youngjoo Kwon
Journal:  Arch Pharm Res       Date:  2021-05-28       Impact factor: 6.010

Review 9.  Dissecting the Role of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis: Cause or Solution.

Authors:  Anna Valeria Samarelli; Roberto Tonelli; Irene Heijink; Aina Martin Medina; Alessandro Marchioni; Giulia Bruzzi; Ivana Castaniere; Dario Andrisani; Filippo Gozzi; Linda Manicardi; Antonio Moretti; Stefania Cerri; Riccardo Fantini; Luca Tabbì; Chiara Nani; Ilenia Mastrolia; Daniel J Weiss; Massimo Dominici; Enrico Clini
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

10.  Loss of MT1-MMP in Alveolar Epithelial Cells Exacerbates Pulmonary Fibrosis.

Authors:  Luis Placido; Yair Romero; Mariel Maldonado; Fernanda Toscano-Marquez; Remedios Ramírez; Jazmín Calyeca; Ana L Mora; Moisés Selman; Annie Pardo
Journal:  Int J Mol Sci       Date:  2021-03-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.